Drug comparisons
Alogliptin vs Rosiglitazone
Alogliptin is a DPP-4 inhibitor with black box warning for type 2 diabetes, while Rosiglitazone is a TZD without black box that improves insulin sensitivity.
No comparison dimensions are available for this page.
Clinical context
Patients with type 2 diabetes who have not achieved adequate glycemic control with metformin or other first-line agents.
Bottom line
Both Alogliptin and Rosiglitazone are effective antidiabetic medications for type 2 diabetes but should be selected based on individual patient factors.
All medication comparisons